Hormones and Agents Affecting Hormonal Mechanism: Calcium Regulating Agents
IFORT2 “Forteo for injection” 250 mcg/ml; 3 ml/pre-filled syringe
適應症：停經後婦女骨質疏鬆症具高度骨折風險者，男性原發性或次發於性腺功能低下症之骨質疏鬆且具有高度骨折風險者。
Usual dose: SC, 20 mcg qd.
Contraindication:
Paget’s disease of bone, unexplained elevations of alkaline phosphatase, prior history of radiation therapy involving the skeleton, bone metastases or a history of skeletal malignancies, metabolic bone diseases (other than osteoporosis), pre-existing hypercalcemia, children or adolescents with open epiphyses.
Precaution:
Active or recent urolithiasis, p’ts on digitalis; hepatic, renal or cardiac impairment; orthostatic hypotension, hypercalcemia.
Adverse effect:
Common: hypotension, syncope, rash, sweating symptom, hyperuricemia, constipation, diarrhea, indigestion, nausea, vomiting, arthralgia, spasm, asthenia, dizziness, increasing frequency of cough, pharyngitis, rhinitis.
Serious: angina.
健保使用規範：限用於
1.停經後骨質疏鬆婦女。(101/7/1)
2.原發性或次發於性腺功能低下症造成骨質疏鬆之男性。
3.需符合下列條件：
(1)引起脊椎或髖部多於2 (含)處骨折，經評估（須於病歷載明）無法耐受副作用或在持續配合使用抗骨質吸收劑至少連續12個月的情況下仍發生至少1處新的骨折之病患。
(2)骨質疏鬆之程度，須經DXA 檢測 BMD 之T score 小於或等於-3.0SD。
4.使用不得超過18支並於二年內使用完畢，使用期間內不得併用其他骨質疏鬆症治療藥物。